{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:44:38Z","timestamp":1748367878345,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>PRESTO 3 evaluated nurses\u2019 preference for the Somatuline\u00ae Autogel\u00ae syringe versus the Lanreotide Pharmathen syringe after injection-pad testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This international simulated-use study included oncology\/endocrinology nurses with\u2009\u2265\u20091\u00a0years\u2019 experience in managing neuroendocrine tumours (NETs) and\/or acromegaly. Each nurse tested both syringes twice in a randomised order before completing an electronic survey. The primary objective was to assess overall preference (%, 95% confidence interval [CI]) for the Somatuline Autogel syringe versus the Lanreotide Pharmathen syringe. Secondary objectives included rating syringe performance and ranking the importance of syringe attributes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ninety-four nurses were enrolled: mean age, 41.0 (SD, 11.5) years. The percentage of nurses stating a preference (\u201cstrong\u201d or \u201cslight\u201d) for the Somatuline Autogel syringe (86.2% [95% CI 77.5\u201392.4%]) was significantly higher than 50% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Performance rating was significantly higher for the Somatuline Autogel syringe versus Lanreotide Pharmathen syringe for 10 of the 11 attributes tested (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The syringe attributes considered most important when injecting patients in routine clinical practice were \u201ceasy to use from preparation to injection\u201d (30.9%) and \u201ccomfortable to handle during use from preparation to injection\u201d (16.0%). The attribute most commonly rated as least important was \u201cfast administration from preparation to injection\u201d (26.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Nurses strongly preferred the user experience of the Somatuline Autogel syringe over the Lanreotide Pharmathen syringe. \u201cEase of use\u201d and \u201ccomfortable to handle\u201d were the most important syringe attributes, and performance rating was significantly higher with Somatuline Autogel versus Lanreotide Pharmathen syringe for all but one attribute.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02158-5","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T03:25:57Z","timestamp":1691465157000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An international simulated-use study to assess nurses\u2019 preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3)"],"prefix":"10.1007","volume":"47","author":[{"given":"D.","family":"Ferone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-8986","authenticated-orcid":false,"given":"A.","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pommie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-5786","authenticated-orcid":false,"suffix":"Jr","given":"A.","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"A. B.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"issue":"2","key":"2158_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172\u2013185","journal-title":"Neuroendocrinology"},{"key":"2158_CR2","unstructured":"The North American Neuroendocrine Tumor Society (NANETS) Guidelines Compendium. https:\/\/nanets.net\/images\/guidelines\/21513_NANETS_2022_Guidelines_Compendium.pdf"},{"issue":"11","key":"2158_CR3","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"key":"2158_CR4","unstructured":"Novartis Pharmaceuticals UK Ltd (2022) Summary of product characteristics, Sandostatin\u00ae LAR\u00ae 10 mg, 20 mg or 30 mg powder and solvent for suspension for injection. https:\/\/www.medicines.org.uk\/emc\/product\/1038\/smpc. Accessed 16 Dec 2022"},{"key":"2158_CR5","unstructured":"Novartis Pharmaceuticals Corporation (2021) Prescribing Information, Sandostatin\u00ae LAR Depot (octreotide acetate) for injectable suspension, for gluteal intramuscular use 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021008s041lbl.pdf. Accessed 16 Dec, 2022"},{"key":"2158_CR6","unstructured":"Ipsen Ltd (2022) Summary of product characteristics, Somatuline Autogel 60 mg, 90 mg, 120 mg, solution for injection in a prefilled syringe. https:\/\/www.medicines.org.uk\/emc\/product\/4808\/smpc. Accessed 16 Dec, 2022"},{"key":"2158_CR7","unstructured":"Ipsen Pharma Biotech (2019) Prescribing Information, Somatuline\u00aeDepot (lanreotide) injection for subcutaneous use 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022074s024lbl.pdf. Accessed 16 Dec, 2022"},{"key":"2158_CR8","unstructured":"Advanz Pharma Group (2021) Summary of product characteristics, Myrelez 60 mg, 90 mg or 120 mg, solution for injection in a prefilled syringe. https:\/\/mri.cts-mrp.eu\/portal\/details?productnumber=DK\/H\/3027\/002. Accessed 16 Dec, 2022"},{"key":"2158_CR9","unstructured":"Cipla USA Inc (2021) Prescribing Information, Lanreotide injection, for subcutaneous use 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215395s000lbl.pdf. Accessed 16 Dec, 2022"},{"issue":"12","key":"2158_CR10","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s12325-019-01112-3","volume":"36","author":"DT Adelman","year":"2019","unstructured":"Adelman DT, Van Genechten D, Megret CM, Truong Thanh XT, Hand P, Martin WA (2019) Co-creation of a lanreotide autogel\/depot syringe for the treatment of acromegaly and neuroendocrine tumours through collaborative human factor studies. Adv Ther 36(12):3409\u20133423","journal-title":"Adv Ther"},{"issue":"4","key":"2158_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s12325-020-01255-8","volume":"37","author":"D Adelman","year":"2020","unstructured":"Adelman D, Truong Thanh XM, Feuilly M, Houchard A, Cella D (2020) Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adv Ther 37(4):1608\u20131619","journal-title":"Adv Ther"},{"key":"2158_CR12","doi-asserted-by":"crossref","unstructured":"O\u2019Toole D, Kunz PL, Webb SM, Goldstein G, Khawaja S, McDonnell M, Boiziau S, Gueguen D, Houchard A, Ribeiro-Oliveira A, Prebtani A (2023) PRESTO 2: an international survey to evaluate patients\u2019 injection experiences with the latest devices\/formulations of long-acting somatostatin analog therapies for neuroendocrine tumors or acromegaly. Adv Ther 40(2):670\u2013690","DOI":"10.1007\/s12325-022-02360-6"},{"key":"2158_CR13","first-page":"103","volume":"5","author":"DT Adelman","year":"2012","unstructured":"Adelman DT, Burgess A, Davies PR (2012) Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl) 5:103\u2013109","journal-title":"Med Devices (Auckl)"},{"issue":"3","key":"2158_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1530\/eje.0.1510317","volume":"151","author":"O Alexopoulou","year":"2004","unstructured":"Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151(3):317\u2013324","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2158_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1177\/1078155219839458","volume":"25","author":"P Ryan","year":"2019","unstructured":"Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G (2019) Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: an observational time and motion analysis. J Oncol Pharm Pract 25(6):1425\u20131433","journal-title":"J Oncol Pharm Pract"},{"key":"2158_CR16","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/PPA.S213472","volume":"13","author":"T Strom","year":"2019","unstructured":"Strom T, Kozlovacki G, Myrenfors P, Almquist M (2019) Patient and nurse experience of using somatostatin analogues to treat gastroenteropancreatic neuroendocrine tumors: results of the somatostatin treatment experience trial (STREET). Patient Prefer Adherence 13:1799\u20131807","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"2158_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12325-020-01600-x","volume":"38","author":"D Cella","year":"2021","unstructured":"Cella D, Evans J, Feuilly M, Neggers S, Van Genechten D, Herman J, Khan MS (2021) Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. Adv Ther 38(2):969\u2013993","journal-title":"Adv Ther"},{"key":"2158_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/PPA.S34337","volume":"6","author":"V Johanson","year":"2012","unstructured":"Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J, Wall N, Gronbaek H, Florholmen J, Ohberg A, Granberg D (2012) Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel\u00ae given by either self\/partner or a health care professional. Patient Prefer Adherence 6:703\u2013710","journal-title":"Patient Prefer Adherence"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02158-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T02:19:53Z","timestamp":1707704393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02158-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02158-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DF: Advisory Board Member; Novartis-AAA, Recordati, Camurus, Sandoz. Speaker; Novartis-AAA, Recordati, Camurus, Sandoz. WM: Has received speakers fees from Advanced Accelerators Applications (a Novartis company) and Ipsen. JW: Nothing to disclose. AH: Employee; Ipsen. Stock Owner; Ipsen. CP: Employee; Ipsen. Stock Owner; Ipsen. ARO: Employee; Ipsen. Stock Owner; Ipsen. ABG: Advisory Board fees; Ipsen; lecture fees from AAA (Novartis) and Recordati.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The survey was conducted in compliance with relevant regulations, including the Epidemiological Studies published by the Council for International Organizations of Medical Sciences (12). Institutional Review Board review was not required due to the design of the study (simulated-use study and no involvement of patients).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}